SNDL vs Trulieve Cannabis
SNDL and TRLV side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SNDL and TRLV compare
SNDL grew revenue faster over the last twelve months (2.8% versus −3.9% for Trulieve Cannabis).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SNDL | TRLV |
|---|---|---|
| Size and price | ||
| Market cap | – | $1.9B |
| Share price | $1.34 | $10.07 |
| Change, 1 year | −20.2% | 85.7% |
| Change, 5 years | −79.5% | −65.5% |
| Beta (5Y) | 0.39 | 0.04 |
| Employees | 2,607 | 5,000 |
| StockData Score | ||
| Total score | 5 | 5 |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 3 (better) | 0 |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 1.7× |
| P/FCF | – | 9.6× |
| FCF yield | – | 10.4% |
| Fair value | – | $15.06 |
| Margin of safety | – | 33.2% |
| Growth | ||
| Revenue growth (TTM) | 2.8% (better) | −3.9% |
| Revenue growth, 5Y average | 73.1% (better) | 17.8% |
| Profitability | ||
| Gross margin | 27.3% | 59.5% (better) |
| Operating margin | −0.67% (better) | −24.3% |
| Net margin | −1.7% | – |
| FCF margin | 6.1% | 17.8% (better) |
| Return on equity | −1.4% | – |
| Return on invested capital | −0.57% | – |
| Financial health | ||
| Interest coverage | −0.9× (better) | −4.9× |
| Current ratio | 4.88 | 5.94 (better) |
| Altman Z-score | – | 0.38 |
| Piotroski F-score | 7 | – |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 18.6% | 20.1% |
| Held by insiders | 0.00% | 5.3% |
| Insider net buying, 12 months | – | −$14.7M |
| Short interest, % of float | – | 2.1% |
Go deeper
- SNDL stock overview
- SNDL income statement
- SNDL valuation and score
- TRLV stock overview
- TRLV income statement
- TRLV valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.